Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
100.57
132.77
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals PLC
Cash & Cash Equivalents
Jazz Pharmaceuticals PLC
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Cash & Cash Equivalents
$2.2B
|
CAGR 3-Years
60%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Cash & Cash Equivalents
$1.5B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
30%
|
CAGR 10-Years
5%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Cash & Cash Equivalents
$28.6m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
2%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Cash & Cash Equivalents
$78.4m
|
CAGR 3-Years
137%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Cash & Cash Equivalents
€54.6m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
7%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Cash & Cash Equivalents
€2.9m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-11%
|
|
Jazz Pharmaceuticals PLC
Glance View
Jazz Pharmaceuticals PLC is a dynamic biopharmaceutical company that specializes in developing and commercializing innovative products to address unmet medical needs, particularly in the areas of sleep medicine and neurology. Founded in 2003 and headquartered in Dublin, Ireland, Jazz has successfully built a diverse portfolio of therapies that include treatments for rare and complex conditions like narcolepsy, which affects sleep quality and overall quality of life. The company's flagship product, Xyrem, has seen robust market success, driving revenue growth and allowing Jazz to expand its research and development efforts across multiple therapeutic areas. In recent years, Jazz has capitalized on strategic acquisitions to enhance its pipeline and broaden its therapeutic focus. Notably, the acquisition of GW Pharmaceuticals in 2021 brought a groundbreaking cannabinoid product, Epidiolex, into its offerings, further cementing the company's position in the market. With a strong emphasis on research and innovation, Jazz Pharmaceuticals is not just a player in today’s market but is poised for future growth as it continues to explore novel treatments across various medical conditions. For investors, Jazz presents an intriguing opportunity, combining a solid business model, a commitment to addressing critical health challenges, and a history of strong financial performance that suggests a promising outlook in the competitive biopharmaceutical landscape.
See Also
What is Jazz Pharmaceuticals PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.2B
USD
Based on the financial report for Sep 30, 2024, Jazz Pharmaceuticals PLC's Cash & Cash Equivalents amounts to 2.2B USD.
What is Jazz Pharmaceuticals PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
50%
Over the last year, the Cash & Cash Equivalents growth was 186%. The average annual Cash & Cash Equivalents growth rates for Jazz Pharmaceuticals PLC have been 60% over the past three years , 50% over the past five years .
You don't have any saved screeners yet
